Menu Search
Equities

Cannabis Poland SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8TE:FRA

Cannabis Poland SA

Actions
  • Price (EUR)0.0214
  • Today's Change-0.001 / -4.04%
  • Shares traded64.96k
  • 1 Year change-68.71%
  • Beta0.7565
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cannabis Poland SA, formerly Telehorse SA, is a Poland-based company engaged in the Pharmaceutical and Medicine Manufacturing activity. The Company focuses on operating in the field of production and sale of pharmaceutical and medical products, with the main focus on vaporization products containing cannabinoids manufactured from cannabis. The Company also expands its activity to include other products than pharmaceuticals, such as cosmetics, oils containing cannabinoids for human and animals and photovoltaic cells. The Company is engaged in research and development of a Cannabidiol (CBD)/ Tetrahydrocannabinol-based (THC-based) pharmaceutical for use in the treatment of seizures associated with drug-resistant epilepsy.

  • Revenue in PLN (TTM)117.08k
  • Net income in PLN-2.17m
  • Incorporated2012
  • Employees--
  • Location
    Cannabis Poland SAul. Jana Styki 23WARSZAWA 03-928PolandPOL
  • Phone+48 221184218
  • Fax+48 222501719
  • Websitehttps://cp-sa.pl/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		CBD:WSE since
announced		Transaction
value
Certis Pharma Sp z o oDeal completed29 Dec 202529 Dec 2025Deal completed-13.16%--
THC Pharma SADeal completed29 Dec 202529 Dec 2025Deal completed-13.16%70.00k
Data delayed at least 15 minutes, as of Feb 16 2026.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.